CN115778875A - Anti-aging skin care composition and preparation method thereof - Google Patents
Anti-aging skin care composition and preparation method thereof Download PDFInfo
- Publication number
- CN115778875A CN115778875A CN202211594885.3A CN202211594885A CN115778875A CN 115778875 A CN115778875 A CN 115778875A CN 202211594885 A CN202211594885 A CN 202211594885A CN 115778875 A CN115778875 A CN 115778875A
- Authority
- CN
- China
- Prior art keywords
- skin
- aging
- ceramide
- skin care
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229940049964 oleate Drugs 0.000 claims abstract description 26
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 26
- 235000011187 glycerol Nutrition 0.000 claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 18
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 10
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 10
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 10
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 8
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 claims abstract description 7
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims abstract description 7
- GCDXVKZXCQGDHC-BLCQCPAESA-N [30-oxo-30-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC GCDXVKZXCQGDHC-BLCQCPAESA-N 0.000 claims abstract description 7
- 229940086668 ceramide eop Drugs 0.000 claims abstract description 7
- 229940106579 hops extract Drugs 0.000 claims abstract description 4
- 239000001906 humulus lupulus l. absolute Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003906 humectant Substances 0.000 claims description 3
- 229940068065 phytosterols Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 108010035532 Collagen Proteins 0.000 abstract description 6
- 102000008186 Collagen Human genes 0.000 abstract description 6
- 229920001436 collagen Polymers 0.000 abstract description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract description 5
- 229940106189 ceramide Drugs 0.000 abstract description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 71
- 240000007817 Olea europaea Species 0.000 description 14
- 229920001202 Inulin Polymers 0.000 description 13
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 13
- 229940029339 inulin Drugs 0.000 description 13
- 230000032683 aging Effects 0.000 description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 7
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 235000004433 Simmondsia californica Nutrition 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- -1 polydimethylsiloxane Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 4
- 108010069502 Collagen Type III Proteins 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 244000025221 Humulus lupulus Species 0.000 description 4
- 235000008694 Humulus lupulus Nutrition 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 241000221095 Simmondsia Species 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940107161 cholesterol Drugs 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 4
- 229940087068 glyceryl caprylate Drugs 0.000 description 4
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960000281 trometamol Drugs 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000218228 Humulus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- GADGVXXJJXQRSA-UHFFFAOYSA-N ethenyl 8-methylnonanoate Chemical compound CC(C)CCCCCCC(=O)OC=C GADGVXXJJXQRSA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 3
- 229940033329 phytosphingosine Drugs 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
- 101710161100 Melanocyte-stimulating hormone receptor Proteins 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 206010048245 Yellow skin Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108091005708 gustatory receptors Proteins 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- RGMZNZABJYWAEC-UHFFFAOYSA-N Methyltris(trimethylsiloxy)silane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C RGMZNZABJYWAEC-UHFFFAOYSA-N 0.000 description 1
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940073663 methyl trimethicone Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
The invention discloses an anti-aging skin care composition, which belongs to the field of skin care products and comprises the following components in percentage by mass: 1,3-propylene glycol, glycerin, hops extract, citric acid 0.1-3%; palmitoyl tripeptide-8.01-2%; phytosterol oleate and phytosterol 0.1-1%; 0.1-2% of rhamnose; ceramide NP, ceramide AP and ceramide EOP 0.01-2%. According to the invention, through the quantitative addition of the effective active ingredients such as the hop extract, ceramide, rhamnose, phytosterol oleate and phytosterol, the skin care composition can meet the basic moisturizing requirement, and can synergistically promote the synthesis of collagen, quickly smooth fine lines of skin and repair damaged skin, so that the anti-aging effect is achieved from multiple factors.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to an anti-aging skin care composition and a preparation method thereof.
Background
Aging is a physiological phenomenon. The skin is located on the body surface and is one of the most prominent organs in the aging process of the body. The main characteristics of human aging are: thinning of skin, appearance of wrinkles, reduction in skin elasticity, pigmentation, muscular atrophy, reduction in skin water retention, and the like. At present, people live more stably and richly, the requirement for beautifying the appearance is higher and higher, and people want to keep youthful forever, so that various anti-aging methods such as anti-aging medicines and anti-aging cosmetics are searched for in all directions. Although some chemically synthesized anti-aging drugs used clinically have a certain effect of delaying aging, the drugs also cause great damage to the organism of a patient. Commercially available anti-aging cosmetics generally have poor anti-aging effects, or contain various chemically synthesized hormones, are easily harmful to the body, and are difficult to meet the requirements of aesthetic people.
Compared with anti-aging drugs, the cosmetic is more convenient and safer to apply and is favored by people. The principle of action of cosmetic anti-aging products is to bring the balance of skin regeneration and degeneration to a normal state, i.e., to increase the synthesis of collagen and elastin. For example, patent CN201710261734.9 discloses a double-layer essence with repairing and anti-aging effects, and its preparation method and application, the essence is composed of hydrogenated castor oil, methyl trimethicone, dioctyl carbonate, cetyl dimethicone, sunflower seed oil, glycerin, sodium hyaluronate, extract of leaves/stems of malacia, polypeptide containing palmitoyl tripeptide and palmitoyl tetrapeptide, lactobacillus fermentation lysate, glycosphingolipids, glyceryl caprylate, p-hydroxyacetophenone, and glyceryl laurate. The essence can play a role in repairing and resisting aging, but the formula is special, can only be used in a specific product, can only act on one or more anti-aging factors, and has a not particularly obvious anti-aging effect.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides an anti-aging skin care composition and a preparation method thereof.
According to the invention, through the quantitative addition of the effective active ingredients such as the hop extract, ceramide, rhamnose, phytosterol oleate and phytosterol, the skin care composition can meet the basic moisturizing requirement, can synergistically promote the synthesis of collagen, quickly smooth fine lines of the skin and repair damaged skin, and can achieve an anti-aging effect from multiple factors, thereby achieving the purpose of delaying skin aging.
The purpose of the invention can be realized by the following technical scheme:
an anti-aging skin care composition comprises A, B, C, D, E and F phases, wherein the anti-aging skin care composition comprises the following components in percentage by mass:
phase A comprises 1.5% of mixture of cetearyl olive oleate and sorbitan olive oleate; 5% of cetyl ethylhexanoate; 2% of squalane; jojoba (SIMMONDSIA CHINENSIS) seed oil 1%; 1% of polydimethylsiloxane; 0.2% of tocopherol acetate; 0.5% of a mixture of plant remained alcohol oleate and plant remained alcohols, and 4% of triglyceride (ethyl hexanoate);
phase B comprises 69.2% of water and 0.3% of acrylic acid (ester)/isodecyl vinyl ester cross-linked polymer; 0.5% of a mixture of glycerol and inulin lauryl carbamate; 4% of glycerol; 3% of trehalose;
phase C comprises 4% of butanediol; 0.2 percent of p-hydroxyacetophenone;
the phase D comprises 0.3 percent of tromethamine; 0.4% of a mixture of sodium polyacrylate, ethylhexyl stearate and trideceth-6;
the phase E comprises 0.2% of a mixture of octyl glycol and ethylhexyl glycerol; 1,2-hexanediol, 1,3-propanediol, 0.4% mixture of glyceryl caprylate and caprylhydroxamic acid;
phase F comprises 0.5% of a mixture of water, sodium lauroyl lactylate, ceramide NP, phenoxyethanol, ceramide AP, phytosphingosine, cholesterol, carbomer, xanthan gum, ethylhexyl glycerol and ceramide EOP; 0.3% of a mixture of rhamnose and water; 1,3-mixture of propylene glycol, glycerol, hops (Humulus LUPULUS) extract and citric acid 1%; 0.5% of a mixture of butanediol, water and palmitoyl tripeptide-8.
The ceramide NP, the ceramide AP and the ceramide EOP have the following functional effects: the lipid concentrate with the same natural composition as human skin improves the barrier function of the skin, and is particularly ideal for dry, sensitive and aged skin; a most bioavailable lipid mixture, a concentrate having substantially the same composition as the skin lipid; ceramide 1+3+6, cholesterol, fatty acid; plant sphingosine recombines lipoid barrier structure, multilayer structure and liquid crystal structure of skin; is designed specifically for skin absorption of ceramide, remodeling of skin barrier function, enhanced moisture retention and skin protection.
1,3-propylene glycol, glycerin, hops (Humulus LUPULUS) extract and citric acid, having the following functional effects: the components can activate bitter taste receptors of skin, and are beneficial to relieving symptoms of allergy, dermatitis, eczema and the like of problematic skin; sensory cosmetic, a new method of calming sensitive and reactive skin; using Senseryn TM Activation of sensory bitter taste receptors (T2 Rs) in skin, first tested on fibroblasts, senseryn TM The protective barrier of the skin can be effectively strengthened; senseryn TM Effects in reducing skin reactivity affecting quality of life; the skin has specificity tendency after use; enhancing all protective barriers of the skin by activating sensory bitter receptors, preventing and delaying inflammatory reactions, preventing and reducing redness, restoring calmness and comfort to the skin, calming the skin with taste; the reactive skin is more resistant, the anti-dermatitis microbiota is optimized, the double infection is prevented, and the inflammation sequelae are prevented; is rich in polyphenol, and has antioxidant and antibacterial effects.
Wherein, the palmitoyl tripeptide-8 has the following functional effects: competitively binds to MC1-R receptors to inhibit inflammatory factor release; the stimulation tolerance of the skin is improved, and the immune barrier of the skin is strengthened; deep penetration: after the liposome is coated, the proportion of the soothing peptide which penetrates through the stratum corneum to reach the epidermis can be increased, and the small-particle-size microcapsules with the particle size of 10-200nm of the liposome can easily enter the skin; slow release and long acting: the soothing peptide can keep higher concentration in the liposome and can be slowly released, so that the action duration of the soothing peptide is prolonged, and the aim of lasting effect is fulfilled; and (3) more stable: after the soothing peptide is embedded by the liposome, the contact with the external environment (such as pH, oxygen and the like) can be reduced, so that the protecting effect is achieved; the method is easy to apply: obviously improves the solubility of the compound in aqueous solution and reduces the problem of formula precipitation.
Rhamnose is used as glycosylation end product blocker to reverse aging, prevent skin yellowing, protect protein, repair glycosylated protein, prevent aging induced by saccharification, tighten and soften skin, reduce dark yellow skin color, treat and prevent aging, care skin in day and night, tighten facial and body skin, remove wrinkles, and brighten skin luster.
Further, cetearyl olive oleate and sorbitan olive oleate are used as emulsifiers in phase a; cetyl ethylhexanoate, squalane, jojoba (SIMMONDSIA CHINENSIS) seed oil, dimethicone, and glyceryl tri (ethylhexanoate) ester as emollient; tocopheryl acetate, phytosterol oleate and phytosterols are used as skin conditioners.
The phytosterol oleate and phytosterol can reduce lipoprotein, enhance lipase activity, prevent erythema, inhibit skin inflammation, keep skin surface moisture, and prevent skin aging.
Further, water in the B phase is used as a solvent; acrylic acid (ester)/vinyl isodecanoate crosslinked polymer is used as thickening agent; a mixture of glycerol and inulin lauryl carbamate was used as emulsifier; glycerin is used as a humectant; trehalose is used as a skin conditioner.
Further, butanediol in the C phase is used as a humectant; p-hydroxyacetophenone is used as an antioxidant.
Further, tromethamine in phase D is used as a pH regulator; a mixture of sodium polyacrylate, ethylhexyl stearate and trideceth-6 was used as thickener.
Further, each component in the E phase was used as a chelating agent.
Further, each ingredient in phase F was used as a skin conditioner.
The anti-aging skin care composition is prepared by the following method:
s1, adding inulin lauryl carbamate in the phase B into glycerol, and dispersing uniformly in advance to obtain an inulin lauryl carbamate mixture;
s2, adding the mixture of cetearyl olive oleate and sorbitan olive oleate in the phase A and the inulin lauryl carbamate in the phase B and water in the phase B into a homogenizing emulsifying pot, and homogenizing and emulsifying at 10000-15000r/min to obtain a first mixture;
and S3, adding all the rest components into the first mixture according to the proportion, and uniformly stirring at 2000-3000r/min to obtain the anti-aging skin care composition.
The invention has the beneficial effects that:
according to the invention, ceramide, including ceramide NP, ceramide AP and ceramide EOP, is added into the composition, and is a lipid concentrate which has the same natural composition with human skin, so that the barrier function of the skin can be improved, and the moisture retention and the skin protection function are improved;
by adding the hop extract to the composition, the extract can enhance all protective barriers of the skin by activating sensory bitter receptors, can prevent and delay inflammatory reactions, can prevent and reduce redness, restore calmness and comfort of the skin, make reactive skin more resistant, optimize anti-dermatitis microbiota, prevent superinfection, prevent inflammatory sequelae; the tea is rich in polyphenol, and has the characteristics of oxidation resistance and bacteria resistance;
inhibiting inflammatory factor release by adding palmitoyl tripeptide-8 to the composition, which is capable of competitively binding to the MC1-R receptor; the stimulation tolerance of the skin is improved, and the immune barrier of the skin is strengthened; the sustained-release tablet has the characteristics of deep penetration and sustained release and long-acting effect, and achieves the effect of lasting effect;
rhamnose is added into the composition as a glycosylation end product blocker to reverse aging, prevent skin yellowing, protect protein, repair glycosylated protein, prevent aging induced by saccharification, compact and soft skin, reduce dark yellow skin color of the skin, treat and prevent aging, care skin at night and in the day, compact face and body skin, remove wrinkles and brighten skin;
by compounding a certain amount of phytosterol oleate and phytosterol in the composition, the composition can reduce lipoprotein, enhance lipase activity, prevent erythema, inhibit skin inflammation, keep skin surface moisture and prevent skin aging;
in conclusion, the invention can ensure that the skin care composition meets the basic moisture retention requirement, and can also synergistically promote the synthesis of collagen, quickly smooth skin fine lines, repair damaged skin and achieve the anti-aging effect from multiple factors by quantitatively adding the effective active ingredients such as the hop extract, the ceramide, the rhamnose, the phytosterol oleate, the phytosterol and the like, thereby achieving the purpose of delaying skin aging.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Preparing an anti-aging skin care composition:
comprising A, B, C, D, E and a phase F, each phase having the following composition:
phase A comprises 1.5g of mixture of cetearyl olive oleate and sorbitan olive oleate; 5g of cetyl ethylhexanoate; 2g of squalane; 1g of jojoba seed oil; 1g of polydimethylsiloxane; 0.2g of tocopherol acetate; 0.5g of a mixture of plant remained alcohol oleate and plant remained alcohols, and 4g of glycerol tri (ethyl hexanoate);
phase B comprises 69.2g of water, 0.3g of acrylic acid (ester)/vinyl isodecanoate crosspolymer; 0.5g of a mixture of glycerol and inulin lauryl carbamate; 4g of glycerol; 3g of trehalose;
phase C comprises 4g of butanediol; 0.2g of p-hydroxyacetophenone;
phase D comprises 0.3g of tromethamine; 0.4g of a mixture of sodium polyacrylate, ethylhexyl stearate and trideceth-6;
the phase E comprises 0.2g of a mixture of octyl glycol and ethylhexyl glycerol; 1,2-hexanediol, 1,3-propanediol, 0.4g of a mixture of glyceryl caprylate and caprylhydroxamic acid;
phase F comprises 0.5g of a mixture of water, sodium lauroyl lactylate, ceramide NP, phenoxyethanol, ceramide AP, phytosphingosine, cholesterol, carbomer, xanthan gum, ethylhexyl glycerol and ceramide EOP; 0.3g of a mixture of rhamnose and water; 1,3-1 g mixture of propylene glycol, glycerin, hops extract and citric acid; 0.5g of a mixture of butanediol, water and palmitoyl tripeptide-8;
the anti-aging skin care composition is prepared by the following method:
s1, adding inulin lauryl carbamate in the phase B into glycerol, and dispersing uniformly in advance to obtain an inulin lauryl carbamate mixture;
s2, adding the mixture of cetearyl olive oleate, sorbitan olive oleate in the phase A, inulin lauryl carbamate in the phase B and water in the phase B into a homogenizing and emulsifying pot, and homogenizing and emulsifying at 10000-15000r/min to obtain a first mixture;
and S3, adding all the rest components into the first mixture according to the proportion, and uniformly stirring at 2000-3000r/min to obtain the anti-aging skin care composition.
Example 2
Preparing the anti-aging skin care composition:
comprising A, B, C, D, E and a phase F, each phase having the following composition:
the phase A comprises 3g of a mixture of cetearyl olive oleate and sorbitan olive oleate; 10g of cetyl ethylhexanoate; 4g of squalane; 2g of jojoba seed oil; 2g of polydimethylsiloxane; 0.4g of tocopherol acetate; 1g of a mixture of plant remained alcohol oleate and plant remained alcohols, and 8g of glycerol tri (ethyl hexanoate);
phase B comprises 138.4g of water and 0.6g of acrylic acid (ester)/vinyl isodecanoate cross-linked polymer; 1g of a mixture of glycerol and inulin lauryl carbamate; 8g of glycerol; 6g of trehalose;
phase C comprises 8g of butanediol; 0.4g of p-hydroxyacetophenone;
phase D comprises 0.6g of tromethamine; 0.8g of a mixture of sodium polyacrylate, ethylhexyl stearate and trideceth-6;
the phase E comprises 0.4g of a mixture of octyl glycol and ethylhexyl glycerol; 1,2-hexanediol, 1,3-propanediol, 0.8g of a mixture of glyceryl caprylate and caprylhydroxamic acid;
phase F comprises 1g of a mixture of water, sodium lauroyl lactylate, ceramide NP, phenoxyethanol, ceramide AP, phytosphingosine, cholesterol, carbomer, xanthan gum, ethylhexyl glycerol and ceramide EOP; 0.6g of a mixture of rhamnose and water; 1,3-mixture of propylene glycol, glycerin, hops extract and citric acid 2g; 1g of a mixture of butanediol, water and palmitoyl tripeptide-8;
the anti-aging skin care composition is prepared by the following method:
s1, adding inulin lauryl carbamate in the phase B into glycerol, and dispersing uniformly in advance to obtain an inulin lauryl carbamate mixture;
s2, adding the mixture of cetearyl olive oleate, sorbitan olive oleate in the phase A, inulin lauryl carbamate in the phase B and water in the phase B into a homogenizing and emulsifying pot, and homogenizing and emulsifying at 10000-15000r/min to obtain a first mixture;
and S3, adding all the rest components into the first mixture according to the proportion, and uniformly stirring at 2000-3000r/min to obtain the anti-aging skin care composition.
1. The skin care products of examples 1-2 were subjected to the following physical and chemical tests:
1. appearance: fine emulsion;
2. pH value: 5.0-7.5;
3. viscosity: 50000-100000mpa.s;
4. the heat resistance stability is inspected (48 ℃ multiplied by 24 hours) and is qualified;
5. and (5) the cold resistance stability is tested (-15 ℃ multiplied by 24 h) and the product is qualified.
2. The anti-wrinkle effects of these samples were evaluated by testing the inhibition rate of MMP-1 by the compositions prepared in examples 1-2: fibroblasts were seeded into 12-well cell culture plates, each well containing 0.87 × 105 cells, and starved for 24 hours in serum-free medium. Starved cultured cells were washed with PBS and treated with uv light (40 mJ). Then, the test sample was added to the cells 2 times within 48 hours. MMP-1 isolated from the medium was measured using a kit (BIOTRAK, RPN 2610). The strength of the anti-wrinkle effect is evaluated by calculating the expression inhibition rate of MMP-1.
Human fibroblasts cultured in a DMEM medium containing 12% FBS were seeded in a 24-well plate, and after cell attachment, medium exchange was performed with a DMEM medium containing 0.22% FBS and 200. Mu.M magnesium ascorbyl phosphate, and the compositions prepared in examples 1-2 were added, respectively. After three days of culture, recovering culture medium supernatant, centrifugally separating, and measuring type III collagen in the obtained supernatant; the evaluation method of the ability of type III collagen in cells to biosynthesize was carried out by measuring the content of the terminal peptide (Procollagen type III-peptide: abbreviated as PIII P) of type III collagen secreted in the supernatant using a "RIA-gnost PIII P (PIIII P) measurement kit". The strength of the anti-wrinkle effect of these samples was evaluated by the promotion rate of collagen type III synthesis.
The compositions obtained in examples 1-2 were subjected to the above-mentioned property tests, and the results are shown in the following table:
| coating amount/mL | Inhibition rate/%) | Promotion rate/%) | |
| Example 1 | 1 | 95.3 | 280.5 |
| Example 2 | 1 | 95.6 | 280.1 |
The data in the table show that the anti-aging skin care composition prepared by the invention has the inhibition rate of MMP-1 of more than 90 percent and has extremely high anti-wrinkle effect; meanwhile, the promotion rate of the collagen synthesis reaches more than 280%, which shows that the skin care composition has a good effect of promoting the collagen synthesis, so that the skin care composition has a high anti-aging effect.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The foregoing is illustrative and explanatory only and is not intended to be exhaustive or to limit the invention to the precise embodiments described, and various modifications, additions, and substitutions may be made by those skilled in the art without departing from the scope of the invention or exceeding the scope of the claims.
Claims (3)
1. The anti-aging skin care composition is characterized by comprising the following components in percentage by mass:
1,3-propylene glycol, glycerin, hops extract, citric acid 0.1-3%;
palmitoyl tripeptide-8.01-2%;
phytosterol oleate and phytosterol 0.1-1%;
0.1-2% of rhamnose;
ceramide NP, ceramide AP, ceramide EOP 0.01-2%;
the balance being water.
2. The anti-aging skin care composition according to claim 1, wherein phytosterol oleate and phytosterols are used as skin conditioners.
3. The anti-aging skin care composition according to claim 1, wherein water is used as a solvent; glycerin is used as a humectant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211594885.3A CN115778875A (en) | 2022-12-12 | 2022-12-12 | Anti-aging skin care composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211594885.3A CN115778875A (en) | 2022-12-12 | 2022-12-12 | Anti-aging skin care composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115778875A true CN115778875A (en) | 2023-03-14 |
Family
ID=85419591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211594885.3A Pending CN115778875A (en) | 2022-12-12 | 2022-12-12 | Anti-aging skin care composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115778875A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116172893A (en) * | 2023-03-20 | 2023-05-30 | 武汉二十四桥生物科技有限公司 | Anti-aging composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481338A (en) * | 2019-01-04 | 2019-03-19 | 上海彤颜实业有限公司 | Moisturizing maintenance composition and preparation method comprising ceramide and phytosterol |
| CN113368018A (en) * | 2020-03-10 | 2021-09-10 | 盈妆生物科技(上海)有限公司 | Anti-inflammatory acne-removing composition and preparation method thereof |
| CN115054565A (en) * | 2022-08-01 | 2022-09-16 | 广州市柏姿生物科技有限公司 | Soothing repair cream for constructing skin barrier |
-
2022
- 2022-12-12 CN CN202211594885.3A patent/CN115778875A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481338A (en) * | 2019-01-04 | 2019-03-19 | 上海彤颜实业有限公司 | Moisturizing maintenance composition and preparation method comprising ceramide and phytosterol |
| CN113368018A (en) * | 2020-03-10 | 2021-09-10 | 盈妆生物科技(上海)有限公司 | Anti-inflammatory acne-removing composition and preparation method thereof |
| CN115054565A (en) * | 2022-08-01 | 2022-09-16 | 广州市柏姿生物科技有限公司 | Soothing repair cream for constructing skin barrier |
Non-Patent Citations (4)
| Title |
|---|
| 广东药大检测技术服务有限公司: "神经酰胺复合物在配方中的保湿修护功效评价", Retrieved from the Internet <URL:《https://mp.weixin.qq.com/s/Urd6aRRZHjf6gMl8lji5Vg》> * |
| 广州诺然: "为皮肤减负，你抓住精髓了吗？", Retrieved from the Internet <URL:《https://mp.weixin.qq.com/s/Nvckxa9BPgpO_cWmB-Sp-A》> * |
| 汀兰生物: "TeeCalmin Rhamnose 鼠李糖", Retrieved from the Internet <URL:《https://mp.weixin.qq.com/s/8rKtWRETPryvOIVmJMvEdA》> * |
| 润辉生物技术威海有限公司: "消炎抗敏因子---棕榈酰三肽-8", Retrieved from the Internet <URL:《https://mp.weixin.qq.com/s/wSYIPZmDoopYfCn9zhs3Bw?poc_token=HOKjm2Wjl84YxFsHLmopu-PwQ4Y_s2mp9Gtzdunp》> * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116172893A (en) * | 2023-03-20 | 2023-05-30 | 武汉二十四桥生物科技有限公司 | Anti-aging composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111956591B (en) | Anti-allergy, soothing and skin color improving cosmetic composition and preparation method thereof | |
| CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
| CN111700853B (en) | Cosmetic composition with anti-allergy repairing effect and application thereof | |
| CN110013447B (en) | Cream for removing striae gravidarum and preparation method thereof | |
| CN109288764B (en) | Hydrolat spray and preparation method thereof | |
| CN111000748A (en) | Polypeptide repairing cream and preparation method thereof | |
| CN110691630A (en) | Use of extract of rambutan peel for moisturizing skin and/or mucous membranes | |
| US20170100320A1 (en) | Composition for external use skin preparation, containing thioredoxin | |
| CN110755328A (en) | Beautifying, moisturizing and repairing composition and application thereof | |
| CN115105453A (en) | Skin care product with antibacterial, anti-inflammatory and repairing functions and preparation method thereof | |
| CN110721148A (en) | Multidirectional pulling and tightening polypeptide essence and preparation method thereof | |
| CN114306161B (en) | Anti-aging composition and preparation method and application thereof | |
| CN112641692A (en) | Anti-allergy repairing composition and preparation method and application thereof | |
| KR101860109B1 (en) | Skin external composition containing floral ginsenoside | |
| CN115154375A (en) | Stable cleaning composition with repairing and relieving effects | |
| CN115778875A (en) | Anti-aging skin care composition and preparation method thereof | |
| KR101474340B1 (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
| CN110075003A (en) | A kind of moisturizing content in freckle cream and preparation method thereof containing beta glucan | |
| CN111388394B (en) | Biphase freeze-dried powder solvent and preparation method and application thereof | |
| KR101639578B1 (en) | Cosmetic composition containing Ocimum basilicum seed extract | |
| KR102443283B1 (en) | Cosmetic composition with excellent skin barrier using skin microbiome | |
| CN114712285B (en) | Composition with anti-wrinkle effect and preparation method and application thereof | |
| CN114632045B (en) | Anti-aging composition, preparation method and application | |
| CN114903810B (en) | Peptide-containing anti-wrinkle composition and application thereof | |
| KR20230135528A (en) | Cosmetic compositions comprising astaxanthin, epidermal growth factor and mixed extracts of natural product as effective components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |